The patient-specific DCVax®-L vaccine is manufactured from a patient’s own white blood cells, which are exposed to cells from the patient’s tumor so they “learn” to recognize brain cancer cells. When re-injected under the patient’s skin, the vaccine’s white blood cells “teach” the immune system to recognize brain cancer cells. A one- or two-year supply of the vaccine is manufactured, and it is used in conjunction with radiation therapy and chemotherapy. In early trials, the vaccine has doubled the median survival time.
The study is officially called a Phase II Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM).
Key Eligibility Criteria:
Patients must be:
- 18 to 70 years old
- Not participating in any other clinical trial for malignant brain tumors
- Eligible for post-surgical treatment with radiotherapy and temozolomide.
This Phase II trial is designed to evaluate the safety, clinical response and survival of patients following treatment with DCVax®-Brain, an immunotherapy treatment for GBM. The experimental therapy uses a patient’s own tumor lysate and white blood cells from which precursors of the dendritic cells are isolated. T The dendritic cell is the starter engine of the immune system. The white cells are then made into dendritic cells and they are educated to “teach” the immune system how to recognize brain cancer cells.